The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
 
Yin Li
No Relationships to Disclose
 
Jianjun Qin
No Relationships to Disclose
 
Liyan Xue
No Relationships to Disclose
 
Anlin Hao
No Relationships to Disclose
 
Tao Jiang
No Relationships to Disclose
 
Shuoyan Liu
No Relationships to Disclose
 
Hongjing Jiang
No Relationships to Disclose
 
Mingqiang Kang
No Relationships to Disclose
 
Hecheng Li
No Relationships to Disclose
 
Hui Tian
No Relationships to Disclose
 
Junke Fu
No Relationships to Disclose
 
Jianqun Ma
No Relationships to Disclose
 
Maoyong Fu
No Relationships to Disclose
 
Yongtao Han
No Relationships to Disclose
 
Longqi Chen
No Relationships to Disclose
 
Lijie Tan
No Relationships to Disclose
 
Tianyang Dai
No Relationships to Disclose
 
Yongde Liao
No Relationships to Disclose
 
Weiguo Zhang
No Relationships to Disclose
 
Bin Li
No Relationships to Disclose